Published in Dis Markers on September 26, 2013
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel) (2017) 0.76
Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol (2003) 6.04
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (2003) 5.47
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Hyperuricemia induces endothelial dysfunction. Kidney Int (2005) 5.36
Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol (2005) 3.73
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 3.25
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet (2002) 2.92
Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation (2002) 2.65
Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol (1990) 2.27
Endothelial function and oxidative stress in cardiovascular diseases. Circ J (2009) 2.26
Worldwide implementation of the WHO Child Growth Standards. Public Health Nutr (2012) 2.08
Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide (1997) 1.85
Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol (2006) 1.74
Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol (2008) 1.69
Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol (1999) 1.65
Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr (2012) 1.48
Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med (2003) 1.45
Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol (2006) 1.33
Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int (1997) 1.28
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag (2009) 1.24
The height-, weight-, and BMI-for-age of Polish school-aged children and adolescents relative to international and local growth references. BMC Public Health (2010) 1.23
Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.20
Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem (2010) 1.19
Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis (2009) 1.07
Association between endothelial dysfunction and hyperuricaemia. Rheumatology (Oxford) (2010) 1.03
Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens (2011) 1.03
Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta (2003) 1.01
Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide (2011) 0.96
Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med (2003) 0.95
Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab (2004) 0.94
Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med (2005) 0.90
Uric acid and the development of hypertension. Med Sci Monit (2010) 0.87
Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome. Atherosclerosis (2010) 0.86
Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf) (2011) 0.83
Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. Pediatr Nephrol (2012) 0.82
Serum uric acid is not an independent risk factor for coronary heart disease. Curr Hypertens Rep (2001) 0.77
Hematological parameters in adolescents with hyperuricemia. Indian Pediatr (2014) 2.00
Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr (2012) 1.48
Assessment of lithogenic risk in children based on a morning spot urine sample. J Urol (2010) 1.45
Polish 2010 growth references for school-aged children and adolescents. Eur J Pediatr (2010) 1.40
KIM-1 and NGAL: new markers of obstructive nephropathy. Pediatr Nephrol (2011) 1.23
Genetic screening in adolescents with steroid-resistant nephrotic syndrome. Kidney Int (2013) 1.21
Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol (2010) 1.11
Perception of health-related quality of life in children with chronic kidney disease by the patients and their caregivers: multicentre national study results. Qual Life Res (2013) 0.94
A new approach to the diagnosis of children's urolithiasis based on the Bonn Risk Index. Pediatr Nephrol (2008) 0.92
Normative data on the Bonn Risk Index for calcium oxalate crystallization in healthy children. Pediatr Nephrol (2007) 0.89
Perivascular epithelioid tumor (PEComa) of the falciform/ broad ligament. Pol J Pathol (2008) 0.87
Does obesity or hyperuricemia influence lithogenic risk profile in children with urolithiasis? Pediatr Nephrol (2014) 0.86
Urinary cytokine profiles in unilateral congenital hydronephrosis. Pediatr Nephrol (2012) 0.84
Characterization of 28 novel patients expands the mutational and phenotypic spectrum of Lowe syndrome. Pediatr Nephrol (2014) 0.83
Urinary angiotensinogen as a marker of intrarenal angiotensin II activity in adolescents with primary hypertension. Pediatr Nephrol (2013) 0.81
Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scand J Urol Nephrol (2010) 0.81
Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatr Nephrol (2008) 0.81
Evaluation of bladder instability in children with recurrent urinary tract infections. Med Sci Monit (2002) 0.81
Assessment of serum cystatin C in children with congenital solitary kidney. Pediatr Nephrol (2006) 0.81
Urinary angiotensinogen as a novel marker of obstructive nephropathy in children. Acta Paediatr (2013) 0.80
Correspondence between Ca²⁺ and calciuria, citrate level and pH of urine in pediatric urolithiasis. Pediatr Nephrol (2013) 0.80
Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy. Pediatr Nephrol (2014) 0.79
Functional bladder capacity and urine osmolality in children with primary monosymptomatic nocturnal enuresis. Scand J Urol Nephrol (2005) 0.79
Epidemiological study of acute poisoning in children: a 5-year retrospective study in the Paediatric University Hospital in Białystok, Poland. Emerg Med J (2012) 0.79
Osteopontin and symmetric dimethylarginine plasma levels in solitary functioning kidney in children. Acta Paediatr (2012) 0.79
Paediatric normative data for urine NGAL/creatinine ratio. Acta Paediatr (2013) 0.78
Psychosocial aspects of children and families of children treated with automated peritoneal dialysis. Pediatr Nephrol (2013) 0.78
Reference values of plasma oxalate in children and adolescents. Pediatr Nephrol (2008) 0.78
Mutational analysis in podocin-associated hereditary nephrotic syndrome in Polish patients: founder effect in the Kashubian population. J Appl Genet (2013) 0.78
Is plasma symmetric dimethylarginine a suitable marker of renal function in children and adolescents? Scand J Urol Nephrol (2011) 0.78
Serum 25-hydroxyvitamin D, osteocalcin, and parathormone status in children with meningomyelocele. Neuropediatrics (2012) 0.77
Urine NGAL and KIM-1 in children and adolescents with hyperuricemia. Pediatr Nephrol (2013) 0.77
Urinary nerve growth factor level in children with neurogenic bladder due to myelomeningocele. Scand J Urol (2013) 0.77
[Serum and urinary homocysteine in children with steroid-dependent nephrotic syndrome]. Pol Merkur Lekarski (2011) 0.77
Serum copeptin levels in adolescents with primary hypertension. Pediatr Nephrol (2013) 0.77
Is symmetric dimethylarginine a sensitive biomarker of subclinical kidney injury in children born with low birth weight? Biomarkers (2014) 0.76
Urinary transforming growth factor beta1 in children and adolescents with congenital solitary kidney. Pediatr Nephrol (2008) 0.76
Urine fibroblast growth factor 23 levels in hypertensive children and adolescents. Croat Med J (2015) 0.76
[FGF23 and Klotho protein--the role in the pathogenesis of hypertension]. Wiad Lek (2015) 0.76
Laminin and transforming growth factor beta-1 in children with vesicoureteric reflux. Pediatr Nephrol (2008) 0.76
Urinary citrate excretion in healthy children depends on age and gender. Pediatr Nephrol (2014) 0.75
Evaluation of Serum Uric Acid: Authors' Reply. Indian Pediatr (2015) 0.75
The effects of breastfeeding on serum asymmetric dimethylarginine levels and body composition in children. Breastfeed Med (2014) 0.75
Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population? Pediatr Nephrol (2014) 0.75
Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children. Dis Markers (2013) 0.75
Normal values for urine renalase excretion in children. Pediatr Nephrol (2014) 0.75
New tubular injury markers in children with a solitary functioning kidney. Pediatr Nephrol (2014) 0.75
Anxiety in children and adolescents with chronic kidney disease--multicenter national study results. Kidney Blood Press Res (2013) 0.75
[The evaluation of urinary tract dysfunction in children with monosymptomatic primary nocturnal enuresis]. Pol Merkur Lekarski (2008) 0.75
[Carriage of Streptococcus pneumoniae in nasopharynx in children with nephrotic syndrome aged 2-5 years in Poland]. Pol Merkur Lekarski (2008) 0.75
Serum and urine fibronectin levels in children with vesicoureteral reflux. Pediatr Nephrol (2007) 0.75
High-sensitivity C-reactive protein and mean platelet volume in paediatric hypertension. Pediatr Nephrol (2010) 0.75
[Serum cystatin C concentration in children with urinary stones]. Pol Merkur Lekarski (2006) 0.75
[Vasculitis of cerebral vessels, probable cause of neurological complications in a child with Schonlein-Henoch purpura]. Pol Merkur Lekarski (2002) 0.75
[Role of matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) in nephrology]. Przegl Lek (2009) 0.75
[Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux]. Pol Merkur Lekarski (2010) 0.75
[Urinary TGF-beta1 excretion in children with renal cysts]. Przegl Lek (2006) 0.75
Spontaneous urinary calcium oxalate crystallization in hypercalciuric children. Pediatr Nephrol (2009) 0.75
Round Table Discussion. Ann Nutr Metab (2016) 0.75
[Differences in dietary habits and food preferences of adults depending on the age]. Rocz Panstw Zakl Hig (2012) 0.75
[Evaluation of inflammatory and renal injury markers in youngest children with pyelonephritis]. Pol Merkur Lekarski (2008) 0.75
[Analysis of vesicoureteral reflux (VUR) course in children]. Pol Merkur Lekarski (2008) 0.75
[Urinary laminin and fibronectin level in children with nephritic syndrome]. Pol Merkur Lekarski (2009) 0.75
[Assessment of fructose-1,6-biphosphatase in urine of children with acute pyelonephritis]. Pol Merkur Lekarski (2004) 0.75
[Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis]. Pol Merkur Lekarski (2009) 0.75
[The role of early-life metabolic programming in the pathogenesis of lifestyle diseases]. Dev Period Med (2015) 0.75
Erratum to: Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy. Pediatr Nephrol (2015) 0.75
Primary soft tissue giant cell tumour of the neck. Cytological and histological characteristics of the tumour and differential diagnosis. Pol J Pathol (2009) 0.75
Urodynamic Findings and Renal Function in Children with Neurogenic Bladder after Myelomeningocele. Urol Int (2015) 0.75
Increased circulating inflammatory markers may indicate that formula-fed children are at risk of atherosclerosis. Acta Paediatr (2014) 0.75